Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994556 | 0.82 | ALOX5 (0.44) | ALOX5GSK3BSMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL27512096 | 0.81 | ALOX5 (0.45) | ALOX5GSK3BFFAR1CTSA | |
| SCHEMBL26444844 | 0.77 | ALOX5 (0.42) | ALOX5GSK3BFFAR1CTSAGAA | |
| SCHEMBL11902940 | 0.77 | ALOX5 (0.51) | ALOX5GSK3BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12261609 | 0.76 | ALOX5 (0.42) | ALOX5GSK3BNPC1RAB9A | |
| SCHEMBL3525769 | 0.74 | ALOX5 (0.40) | ALOX5GSK3BFFAR1CTSAGAA | |
| SCHEMBL27727056 | 0.73 | ALOX5 (0.50) | ALOX5GSK3BFFAR1KDM4E | |
| Maleic Acid SCHEMBL9482727 | 0.73 | SLC15A1 (0.46) | ALOX5CYP2C19 | |
| Fumaric Acid SCHEMBL9482738 | 0.73 | SLC15A1 (0.46) | ALOX5CYP2C19 | |
| SCHEMBL8760194 | 0.72 | SLC6A2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083011-B1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2014-06-04 | — | — | EP | disclosed |
| US-8466191-B2 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof | ZHANG HESHENG (CN) | 2013-06-18 | — | — | US | disclosed |
| CN-101186612-B | Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application | TIANJIN HEMEI BIOLOG TECHNOLOGY CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
| EP-2083011-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-07-29 | — | — | EP | disclosed |
| CN-101186612-A | Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application | TIANJIN HEMEI BIOLOG TECHNOLOG (CN) | 2008-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | ALOX5 242/4885GSK3B 4718/4885SMN1; SMN2 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.